CHA Bundang Medical Center has become the first in Asia (the second in the world) to confirm that the transplantation of human embryonic stem cell (hESC)-derived retinal pigment epithelium (RPE) cells is effective in treating age-related macular degeneration (AMD) and Stargardt disease (juvenile macular degeneration) without causing dangerous side effects. Hence CHA Bundang Medical Center is now on the fast track to developing the world’s first hESC-based therapeutic product.
A Korean research team, led by Professor Song Won-Kyung from CHA Bundang Medical Center, and CHA Biotech (a leading S. Korea-based biotechnology firm focused on stem cell therapies) jointly issued an
Bronchi, bronchial tree, and lungs. (Photo credit: Wikipedia)
How do you grow stem cells into lungs? The question has puzzled scientists for years. First you need the right recipe, and it took BU researchers Darrell Kotton, Tyler Longmire, and Laertis Ikonomou seven years of trial and error and painstaking science to come up with it. “A lot had to happen to make a lung,” says Kotton. “It was a little more complicated than Julia Child’s ‘heat, eat, bon appetit.’”
Kotton is a School of Medicine associate professor of medicine and pathology and codirector of the Center for Regenerative Medicine (CReM),
Researchers have found a gene that could be key to the development of stem cells — cells that can potentially save millions of lives by morphing into practically any cell in the body.
The gene, known as ASF1A, is at least one of the genes responsible for the mechanism of cellular reprogramming, a phenomenon that can turn one cell type into another, which is key to the making of stem cells.
Researchers at the Michigan State University analysed more than 5,000 genes from a human egg, or oocyte, before determining that the ASF1A, along with another gene known as OCT4 and
The Governing Board of the California Institute for Regenerative Medicine, the State Stem Cell Agency, approved a $25 million award to support the first FDA-approved clinical trial based on cells derived from human embryonic stem cells.
The award to Menlo Park-based Geron, Corp, will support the company’s on-going early phase trial for people with spinal cord injury. This is the first time the agency, which was created by the passage of proposition 71 in 2004, has funded a human clinical trial testing a stem cell-derived therapy.
“Supporting the Geron trial is a landmark step for CIRM,” said Robert Klein, CIRM
Scientists at the UCSF-affiliated Gladstone Institutes and an international team of researchers have generated a human model of Huntington’s disease — directly from the skin cells of patients with the disease.
For years, scientists have studied Huntington’s disease primarily in post-mortem brain tissue or laboratory animals modified to mimic the disease. Today, in Cell Stem Cell, the international team shows how they developed a human model of Huntington’s disease, which causes a diverse range of neurological impairments. The new model should help scientists better understand the development of Huntington’s — and provide better ways to identify and screen potential therapeutics